Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007 Jun;9(6):654-9. Epub 2007 May 7. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: Trophic support for axons? Proteomics Clin Appl. 2007 Nov;1(11):1446-61. doi: 10.1002/prca.200700522. Epub 2007 Oct 16. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Proteomic characterization of thymocyte-derived microvesicles and apoptotic bodies in BALB/c mice. J Proteomics. 2011 Sep 6;74(10):2025-33. doi: 10.1016/j.jprot.2011.05.023. Epub 2011 May 19. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Membrane microvesicles as mediators for melanoma-fibroblasts communication: Roles of the VCAM-1/VLA-4 axis and the ERK1/2 signal pathway. Cancer Lett. 2015 Feb 4. pii: S0304-3835(15)00066-X. doi: 10.1016/j.canlet.2015.01.032. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | A comprehensive proteomics analysis reveals a secretory path- and status-dependent signature of exosomes released from tumor associated macrophages. J Proteome Res. 2015 Aug 27. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | A comprehensive proteomics analysis reveals a secretory path- and status-dependent signature of exosomes released from tumor associated macrophages. J Proteome Res. 2015 Aug 27. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Microvesicles provide a mechanism for intercellular communication by embryonic stem cells during embryo implantation. Nat Commun. 2016 Jun 15;7:11958. doi: 10.1038/ncomms11958. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget. 2016 Jul 22. doi: 10.18632/oncotarget.10783. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget. 2016 Jul 22. doi: 10.18632/oncotarget.10783. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Macrophage Foam Cell-Derived Extracellular Vesicles Promote Vascular Smooth Muscle Cell Migration and Adhesion. J Am Heart Assoc. 2016 Oct 17;5(10). pii: e004099. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Macrophage Foam Cell-Derived Extracellular Vesicles Promote Vascular Smooth Muscle Cell Migration and Adhesion. J Am Heart Assoc. 2016 Oct 17;5(10). pii: e004099. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Thymic exosomes promote the final maturation of thymocytes. Sci Rep. 2016 Nov 8;6:36479. doi: 10.1038/srep36479. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell. 2016 Dec 1;167(6):1525-1539.e17. doi: 10.1016/j.cell.2016.11.005. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell. 2016 Dec 1;167(6):1525-1539.e17. doi: 10.1016/j.cell.2016.11.005. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Exploring experimental cerebral malaria pathogenesis through the characterisation of host-derived plasma microparticle protein content. Sci Rep. 2016 Dec 5;6:37871. doi: 10.1038/srep37871. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Exploring experimental cerebral malaria pathogenesis through the characterisation of host-derived plasma microparticle protein content. Sci Rep. 2016 Dec 5;6:37871. doi: 10.1038/srep37871. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions. Sci Signal. 2017 Apr 4;10(473). pii: eaai7696. doi: 10.1126/scisignal.aai7696. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions. Sci Signal. 2017 Apr 4;10(473). pii: eaai7696. doi: 10.1126/scisignal.aai7696. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Increased Release of Apolipoprotein E in Extracellular Vesicles Following Amyloid-beta Protofibril Exposure of Neuroglial Co-Cultures. J Alzheimers Dis. 2017 Aug 17. doi: 10.3233/JAD-170278. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury. Clin Cancer Res. 2017 Oct 25. pii: clincanres.2046.2017. doi: 10.1158/1078-0432.CCR-17-2046. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury. Clin Cancer Res. 2017 Oct 25. pii: clincanres.2046.2017. doi: 10.1158/1078-0432.CCR-17-2046. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential. Proteomics. 2017 Nov 8. doi: 10.1002/pmic.201600370. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential. Proteomics. 2017 Nov 8. doi: 10.1002/pmic.201600370. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential. Proteomics. 2017 Nov 8. doi: 10.1002/pmic.201600370. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential. Proteomics. 2017 Nov 8. doi: 10.1002/pmic.201600370. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. J Proteome Res. 2017 Nov 15. doi: 10.1021/acs.jproteome.7b00646. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. J Proteome Res. 2017 Nov 15. doi: 10.1021/acs.jproteome.7b00646. | ENOG410YDXS | 315 / 0 / 315 |
Keratin, type I cytoskeletal 10 (56 kDa cytokeratin) (Cytokeratin-10) (CK-10) (Keratin, type I cytoskeletal 59 kDa) (Keratin-10) (K10) | P02535 | Exosomes as secondary inductive signals involved in kidney organogenesis. J Extracell Vesicles. 2018 Jan 23;7(1):1422675. doi: 10.1080/20013078.2017.1422675. eCollection 2018. | ENOG410YDXS | 315 / 0 / 315 |